BioXcel Therapeutics presented new positive data from its Phase 3 SERENITY At-Home trial showing that BXCL501, a sublingual dexmedetomidine film, effectively reduces agitation in patients with bipolar disorders or schizophrenia when self-administered at home. The treatment showed benefits across all agitation severity levels, with the strongest effect in severe cases, and maintained effectiveness with repeated dosing over 12 weeks. The FDA has set a target action date of November 14, 2026, for the drug's supplemental New Drug Application for at-home use. If approved, BXCL501 could become the first FDA-approved treatment for acute agitation in the home setting, offering a new option for patients and caregivers.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
